Precision BioSciences Inc (DTIL) stock
DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3058% above fair value
$7.05−0.23 (-3.16%)
Close on Nov 17, 2026Market cap $194.59MP/E –Yield –
Precision BioSciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Precision BioSciences's price to sales ratio was 5.4× on Nov 11, 2026, against 94.2× a year earlier. Over the last 5 years it ranged from 0.4× to 94.2×, with a median of 2.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.4× | −66.6 |
| 2025 | Dec 31, 2025 | 72.0× | +71.6 |
| 2024 | Dec 31, 2024 | 0.4× | −0.4 |
| 2023 | Dec 29, 2023 | 0.8× | −5.5 |
| 2022 | Dec 30, 2022 | 6.3× | +2.6 |
| 2021 | Dec 31, 2021 | 3.8× | −16.2 |
| 2020 | Dec 31, 2020 | 19.9× | −14.1 |
| 2019 | Dec 31, 2019 | 34.1× | – |
See a number that looks wrong?